Published online before print October 13, 2005, doi: 10.1161/01.ATV.0000190660.32863.cd
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis
From the Department of Metabolism, Endocrinology, and Molecular Medicine (H.K., T.S., H.Y., K. Motoyama, K. Mori, S.F., M.E., T.S., Y.N.), Osaka City University Graduate School of Medicine, Osaka, Japan; Daiichi Fine Chemical Co Ltd (H.T., H.M.), Takaoka, Japan; and the Department of Biochemistry and Molecular Vascular Biology (S.S., Y.Y., H.Y., T.W., H.Y.), Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Correspondence to Dr Hidenori Koyama, Department of Metabolism, Endocrinology and Molecular Medicine, (Second Department of Internal Medicine), Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. E-mail hidekoyama{at}med.osaka-cu.ac.jp
Objectives— Advanced glycation endproducts, AGEs, and its specific receptor, RAGE, are involved in diabetic vascular complications. Endogenous secretory RAGE, esRAGE, has been identified as an alternatively spliced form of RAGE, and shown to act as a decoy receptor for AGE. Here, we measured plasma esRAGE level with a recently developed enzyme-linked immunosorbent assay (ELISA) and examined its association with atherosclerosis in age- and gender-matched 203 type 2 diabetic and 134 nondiabetic subjects.
Methods and Results— Plasma esRAGE was inversely associated with carotid or femoral atherosclerosis, as quantitatively measured as intimal-medial thickness (IMT) by arterial ultrasound. Stepwise regression analyses revealed that plasma esRAGE was the third strongest and independent factor associated with carotid IMT, following age and systolic blood pressure. Plasma esRAGE was significantly lower in diabetic patients (0.176±0.092 ng/mL) than nondiabetic controls (0.253±0.111). Of note, in all, diabetic or nondiabetic group, plasma esRAGE was significantly and inversely correlated with components of the metabolic syndrome including body mass index, blood pressure, triglyceride, HbA1c, or an insulin resistance index. Stepwise regression analyses showed that body mass index or insulin resistance index was the major factor determining plasma esRAGE in all, nondiabetic or diabetic population.
Conclusions— esRAGE is a novel and potential protective factor for the metabolic syndrome and atherosclerosis.
Endogenous secretory RAGE, esRAGE, has been identified as an alternatively spliced form of RAGE, and shown to act as a decoy receptor for AGE. Here, we show that plasma esRAGE was inversely and independently associated with carotid atherosclerosis or components of the metabolic syndrome, even in the absence of diabetes.
Key Words: pathophysiology • risk factors • type 2 diabetes
This article has been cited by other articles:
 |
|
 |
|
  M. E. Rubio-Ruiz, E. Diaz-Diaz, M. Cardenas-Leon, R. Arguelles-Medina, P. Sanchez-Canales, F. Larrea-Gallo, E. Soria-Castro, and V. Guarner-Lans Glycation does not modify bovine serum albumin (BSA)-induced reduction of rat aortic relaxation: The response to glycated and nonglycated BSA is lost in metabolic syndrome Glycobiology, July 1, 2008; 18(7): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. I. Hudson, A. M. Carter, E. Harja, A. Z. Kalea, M. Arriero, H. Yang, P. J. Grant, and A. M. Schmidt Identification, classification, and expression of RAGE gene splice variants FASEB J, May 1, 2008; 22(5): 1572 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bengmark Advanced Glycation and Lipoxidation End Products-Amplifiers of Inflammation: The Role of Food JPEN J Parenter Enteral Nutr, September 1, 2007; 31(5): 430 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Yamagishi and T. Imaizumi Serum Levels of Soluble Form of Receptor for Advanced Glycation End Products (sRAGE) May Reflect Tissue RAGE Expression In Diabetes Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): e32 - e32. [Full Text] [PDF]
|
|
|
|
|
|
J. Miura, Y. Yamamoto, M. Osawa, T. Watanabe, H. Yonekura, Y. Uchigata, H. Yamamoto, and Y. Iwamoto Endogenous Secretory Receptor for Advanced Glycation Endproducts Levels Are Correlated With Serum Pentosidine and CML in Patients With Type 1 Diabetes Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 253 - 254. [Full Text] [PDF]
|
|
|
|
|
|
H. Koyama, T. Shoji, S. Fukumoto, K. Shinohara, T. Shoji, M. Emoto, K. Mori, H. Tahara, E. Ishimura, R. Kakiya, et al. Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Basta, A. M. Sironi, G. Lazzerini, S. Del Turco, E. Buzzigoli, A. Casolaro, A. Natali, E. Ferrannini, and A. Gastaldelli Circulating Soluble Receptor for Advanced Glycation End Products Is Inversely Associated with Glycemic Control and S100A12 Protein J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4628 - 4634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shoji, H. Koyama, T. Morioka, S. Tanaka, A. Kizu, K. Motoyama, K. Mori, S. Fukumoto, A. Shioi, N. Shimogaito, et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes, August 1, 2006; 55(8): 2245 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Humpert, S. Kopf, Z. Djuric, T. Wendt, M. Morcos, P. P. Nawroth, and A. Bierhaus Plasma sRAGE Is Independently Associated With Urinary Albumin Excretion in Type 2 Diabetes Diabetes Care, May 1, 2006; 29(5): 1111 - 1113. [Full Text] [PDF]
|
|